After 5 cycles of an antineoplastic regimen, FDG-PET shows a reduced number of lesions with increased FDG uptake in the cervical, thoracic, lumbar, and sacral spinal cord (A). After 9 cycles of intrathecal therapy, an increased number of lesions with elevated uptake of FDG-PET is observed again (B). After 2 additional courses of systemic HD-MTX, FDG-accumulating lesions have disappeared (C).